Trust Company
IMVT icon

Trust Company’s Immunovant IMVT Stock Holding History

Trust Company’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$709 Hold
21
– – ﹤0.01% 671
2026
Q2 		$809 Hold
21
– – ﹤0.01% 639
2026
Q1 		$522 Hold
21
– – ﹤0.01% 699
2025
Q4 		$534 Buy
+21
New +$468 ﹤0.01% 677

Other funds holding IMVT

Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Banque Pictet & Cie
Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
FNY Investment Advisers
FNY Investment Advisers New York $402M AUM 85.34% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
PWMG
Private Wealth Management Group Princeton, New Jersey $445M AUM 13.54% 1-Year Est. Return

Trust Company's IMVT Position: Q3 2026 in Review

Trust Company held its Immunovant (IMVT) position steady in Q3 2026 at 21 shares worth $709. The position accounts for ﹤0.01% of the portfolio, ranked #671.

Trust Company first reported a position in IMVT in Q4 2025 and has held it in 4 quarters since. The position peaked at $809 in Q2 2026. 17 funds tracked by Wall St. Rank hold IMVT as of Q3 2026.

  • Trust Company held 21 shares of Immunovant worth $709 as of Q3 2026.
  • Trust Company left its Immunovant share count unchanged in Q3 2026.
  • Immunovant made up ﹤0.01% of Trust Company's portfolio in Q3 2026, its #671 holding.
  • Trust Company first reported a position in Immunovant in Q4 2025 and has held it in 4 quarters since.
  • Trust Company's Immunovant position peaked at $809 in Q2 2026.
  • 17 funds tracked by Wall St. Rank held Immunovant as of Q3 2026.

Based on Trust Company's 13F filing for Q3 2026, filed 9 Oct 2026.